Tau aggregates as immunotherapeutic targets

Frontiers in Bioscience - Scholar

Volumn 5 S, Issue 2, 2013, Pages 426-438

  Castillo Carranza, Diana L ^a   Lasagna Reeves, Cristian A ^a   Kayed, Rakez ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alzheimer disease; Clearance; Immunotherapy; Review; Tau oligomers

Indexed keywords

AMYLOID BETA PROTEIN; BAPINEUZUMAB; MONOMER; OLIGOMER; TAU OLIGOMER; TAU PROTEIN; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; VACCINE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BETA SHEET; BRAIN STEM; COGNITIVE DEFECT; DISEASE COURSE; HIPPOCAMPUS; HUMAN; IMMUNOTHERAPY; INTERSTITIAL FLUID; MEYNERT BASAL NUCLEUS; MOTOR DYSFUNCTION; NEOCORTEX; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; PAIRED HELICAL FILAMENT; PASSIVE IMMUNIZATION; PERIKARYON; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYNAPTIC INHIBITION; TAUOPATHY; ANIMAL; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; REVIEW;

ALZHEIMER DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; TAU PROTEINS; VACCINES;

EID: 84883242375     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s381     Document Type: Article

References (129)

1. C Ballatore, V M Lee and J Q Trojanowski: Taumediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8(9), 663-72 (2007)
2. V Haroutunian, P Davies, C Vianna, J D Buxbaum and D P Purohit: Tau protein abnormalities associated with the progression of alzheimer disease type dementia. Neurobiol Aging 28(1), 1-7 (2007)
3. Editorial: How much is dementia care worth? The Lancet Neurology Volume 9( Issue 11 ), Page 1037 (2010)
4. F Mangialasche, A Solomon, B Winblad, P Mecocci and M Kivipelto: Alzheimer's disease: clinical trials and drug development. Lancet Neurol 9(7), 702-16 (2010)
5. H Braak and E Braak: Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1(3), 213-6 (1991)
6. H Braak and E Braak: Staging of Alzheimer's diseaserelated neurofibrillary changes. Neurobiol Aging 16(3), 271-8; discussion 278-84 (1995)
7. H Braak and E Braak: Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 165, 3-12 (1996)
8. J Hardy and D J Selkoe: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580), 353-6 (2002)
9. S Lesne, L Kotilinek and K H Ashe: Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience 151(3), 745-9 (2008)
10. H J Aizenstein, R D Nebes, J A Saxton, J C Price, C A Mathis, N. D. Tsopelas, S. K. Ziolko, J. A. James, B E Snitz, P R Houck, W Bi, A D Cohen, B J.Lopresti, S T DeKosky, E M Halligan and W. E. Klunk: Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65(11), 1509-17 (2008)
11. E M Reiman, K Chen, X Liu, D Bandy, M Yu, W Lee, N Ayutyanont, J Keppler, S A Reeder, J B Langbaum, G E Alexander, W E Klunk, C A Mathis, J C Price, H J Aizenstein, S T DeKosky and R J Caselli: Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106(16), 6820-5 (2009)
12. P V Arriagada, J H Growdon, E T Hedley-Whyte and B T Hyman: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42(3 Pt 1), 631-9 (1992)
13. H Braak and E Braak: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4), 239-59 (1991)
14. T Gomez-Isla, R Hollister, H West, S Mui, J H Growdon, R C Petersen, J E Parisi and B T. Hyman: Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41(1), 17-24 (1997)
15. M Hong, V Zhukareva, V Vogelsberg-Ragaglia, Z Wszolek, L Reed, B I Miller, D H Geschwind, T D Bird, D McKeel, A Goate, J C Morris, K C Wilhelmsen, G D Schellenberg, J Q Trojanowski and V M Lee: Mutationspecific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282(5395), 1914-7 (1998)
16. M Hutton, C L Lendon, P Rizzu, M Baker, S Froelich, H Houlden, S Pickering-Brown, S Chakraverty, A Isaacs, A Grover, J Hackett, J Adamson, S Lincoln, D Dickson, P Davies, R C Petersen, M Stevens, E de Graaff, E Wauters, J van Baren, M Hillebrand, M Joosse, J M Kwon, P Nowotny, L K Che, J Norton, J C Morris, L.A Reed, J Trojanowski, H Basun, L Lannfelt, M Neystat, S Fahn, F Dark, T Tannenberg, P R Dodd, N Hayward, J. B. Kwok, P. R. Schofield, A. Andreadis, J. Snowden, D. Craufurd, D. Neary, F. Owen, B. A. Oostra, J. Hardy, A. Goate, J van Swieten, D Mann, T Lynch and P Heutink: Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393(6686), 702-5 (1998)
17. H Braak and K Del Tredici: The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 121(2), 171-81 (2011)
18. R Raschetti, E Albanese, N Vanacore and M Maggini: Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 4(11), e338 (2007)
19. D Schenk, R Barbour, W Dunn, G Gordon, H Grajeda, T Guido, K Hu, J Huang, K Johnson-Wood, K Khan, D Kholodenko, M Lee, Z Liao, I Lieberburg, R Motter, L Mutter, F Soriano, G Shopp, N Vasquez, C Vandevert, S Walker, M Wogulis, T Yednock, D Games and P Seubert: Immunization with amyloid-beta attenuates Alzheimerdisease-like pathology in the PDAPP mouse. Nature 400(6740), 173-7 (1999)
20. J C Dodart, K R Bales, K S Gannon, S J Greene, R B DeMattos, C Mathis, C A DeLong, S Wu, X Wu, D M Holtzman and S M Paul: Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5(5), 452-7 (2002)
21. C Janus, J Pearson, J McLaurin, P M. Mathews, Y Jiang, S D Schmidt, M A Chishti, P Horne, D Heslin, J French, H T Mount, R A Nixon, M Mercken, C Bergeron, P E Fraser, P St George-Hyslop and D Westaway: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408(6815), 979-82 (2000)
22. L A Kotilinek, B Bacskai, M Westerman, T Kawarabayashi, L Younkin, B T Hyman, S Younkin and K H Ashe: Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22(15), 6331-5 (2002)
23. D Morgan, D M. Diamond, P E Gottschall, K E Ugen, C Dickey, J Hardy, K Duff, P Jantzen, G DiCarlo, D Wilcock, K Connor, J Hatcher, C Hope, M Gordon and G W Arendash: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408(6815), 982-5 (2000)
24. I Ferrer, M Boada-Rovira, M L Sanchez-Guerra, M J Rey and F Costa-Jussa: Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14(1), 11-20 (2004)
25. J A Nicoll, D Wilkinson, C Holmes, P Steart, H Markham and R O Weller: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9(4), 448-52 (2003)
26. J M Orgogozo, S Gilman, J F Dartigues, B Laurent, M Puel, L C Kirby, P Jouanny, B Dubois, L Eisner, S Flitman, B F Michel, M Boada, A Frank and C Hock: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1), 46-54 (2003)
27. B Vellas, R Black, L J Thal, N C Fox, M Daniels, G McLennan, C Tompkins, C Leibman, M Pomfret and M Grundman: Long-Term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 6(2), 144-51 (2009)
28. J O Rinne, D J Brooks, M N Rossor, N C Fox, R Bullock, W E Klunk, C A Mathis, K Blennow, J Barakos, A A Okello, S Rodriguez-Martinez de Liano, E Liu, M Koller, K M Gregg, D Schenk, R Black and M Grundman: 11C-PiB PET assessment of change in fibrillar amyloidbeta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9(4), 363-72 (2010)
29. A Schneider and E Mandelkow: Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 5(3), 443-57 (2008)
30. J Marx: Alzheimer's disease. A new take on tau. Science 316(5830), 1416-7 (2007)
31. K. Ubhi and E. Masliah: Recent advances in the development of immunotherapies for tauopathies. Exp Neurol 230(2), 157-61 (2011)
32. C A Lasagna-Reeves, D L Castillo-Carranza, G R Jackson and R Kayed: Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Curr Alzheimer Res 8(6), 659-65 (2011)
33. J Gu and E M Sigurdsson: Immunotherapy for Tauopathies. J Mol Neurosci (2011)
34. R Kayed: Anti-Tau oligomers passive vaccination for the treatment of Alzheimer's disease. Hum Vaccin 6(11), 47-51 (2010)
35. J Q Trojanowski, T Schuck, M L Schmidt and V M Lee: Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem 37(2), 209-15 (1989)
36. M Goedert, M G Spillantini, N J Cairns and R A Crowther: Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8(1), 159-68 (1992)
37. V M Lee, M Goedert and J Q Trojanowski: Neurodegenerative tauopathies. Annu Rev Neurosci 24, 1121-59 (2001)
38. J Avila, I Santa-Maria, M Perez, F Hernandez and F Moreno: Tau phosphorylation, aggregation, and cell toxicity. J Biomed Biotechnol 2006(3), 74539 (2006)
39. L Buee, T Bussiere, V Buee-Scherrer, A Delacourte and P R Hof: Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33(1), 95-130 (2000)
40. A C Alonso, I Grundke-Iqbal and K Iqbal: Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med, 2(7), 783-7 (1996)
41. S E Merrick, J Q Trojanowski and V M Lee: Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons. J Neurosci 17(15), 5726-37 (1997)
42. U Wagner, M Utton, J M Gallo and C C Miller: Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci, 109 ( Pt 6), 1537-43 (1996)
43. E E Congdon, S Kim, J Bonchak, T Songrug, A Matzavinos and J Kuret: Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants. J Biol Chem 283(20), 13806-16 (2008)
44. M Margittai and R Langen: Template-Assisted filament growth by parallel stacking of tau. Proc Natl Acad Sci U S A 101(28), 10278-83 (2004)
45. M E King, V Ahuja, L I Binder and J Kuret: Liganddependent tau filament formation: implications for Alzheimer's disease progression. Biochemistry 38(45), 14851-9 (1999)
46. A Rostagno and J Ghiso: Isolation and biochemical characterization of amyloid plaques and paired helical filaments. Curr Protoc Cell Biol Chapter 3, Unit 3 33 3 33 1-33 (2009)
47. V M Lee, J Wang and J Q Trojanowski: Purification of paired helical filament tau and normal tau from human brain tissue. Methods Enzymol, 309, 81-9 (1999)
48. S Xu, K R Brunden, J Q Trojanowski and V M Lee: Characterization of tau fibrillization in vitro. Alzheimers Dement 6(2), 110-7
49. C A Lasagna-Reeves, D L Castillo-Carranza, M J Guerrero-Muoz, G R Jackson and R Kayed: Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49(47), 10039-41 (2010)
50. J Lee, E K Culyba, E T Powers and J W Kelly: Amyloidbeta forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol 7(9), 602-9 (2011)
51. T R Serio, A G Cashikar, A S Kowal, G J Sawicki, J J Moslehi, L Serpell, M F Arnsdorf and S L Lindquist: Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 289(5483), 1317-21 (2000)
52. M A Meraz-Rios, K I Lira-De Leon, V Campos-Pena, M A De Anda-Hernandez and R Mena-Lopez: Tau oligomers and aggregation in Alzheimer's disease. J Neurochem (2009)
53. A Gomez-Ramos, M Diaz-Hernandez, R Cuadros, F Hernandez and J Avila: Extracellular tau is toxic to neuronal cells. FEBS Lett 580(20), 4842-50 (2006)
54. C A Lasagna-Reeves, D L Castillo-Carranza, U Sengupta, A L Clos, G R Jackson and R Kayed: Tau Oligomers Impair Memory and Induce Synaptic and Mitochondrial Dysfunction in Wild-Type Mice. Mol Neurodegener 6(1), 39 (2011)
55. K R Brunden, J Q Trojanowski and V M Lee: Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J Alzheimers Dis 14(4), 393-9 (2008)
56. Z Berger, H Roder, A Hanna, A Carlson, V Rangachari, M Yue, Z Wszolek, K Ashe, J Knight, D Dickson, C Andorfer, T L Rosenberry, J Lewis, M Hutton and C Janus: Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27(14), 3650-62 (2007)
57. R Kayed and G R Jackson: Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr Opin Immunol 21(3), 359-63 (2009)
58. K Santacruz, J Lewis, T Spires, J Paulson, L Kotilinek, M Ingelsson, A Guimaraes, M DeTure, M Ramsden, E McGowan, C Forster, M Yue, J Orne, C Janus, A Mariash, M Kuskowski, B Hyman, M Hutton and K H Ashe: Tau suppression in a neurodegenerative mouse model improves memory function. Science 309(5733), 476-81 (2005)
59. A Sydow, A Van der Jeugd, F Zheng, T Ahmed, D Balschun, O Petrova, D Drexler, L Zhou, G Rune, E Mandelkow, R D'Hooge, C Alzheimer and E M Mandelkow: Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci 31(7), 2511-25 (2011)
60. C W Wittmann, M F Wszolek, J M Shulman, P M Salvaterra, J Lewis, M Hutton and M B Feany: Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293(5530), 711-4 (2001)
61. R Morsch, W Simon and P D Coleman: Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58(2), 188-97 (1999)
62. T L Spires-Jones, K J Kopeikina, R M Koffie, A de Calignon and B T Hyman: Are Tangles as Toxic as They Look? J Mol Neurosci (2011)
63. R D Terry: Do neuronal inclusions kill the cell? J Neural Transm Suppl 59, 91-3 (2000)
64. J. A. van de Nes, R. Nafe and W. Schlote: Non-Tau based neuronal degeneration in Alzheimer's disease-An immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex. Brain Res, 1213, 152-65 (2008)
65. B A Vogt, L J Vogt, K E Vrana, L Gioia, R S Meadows, V R Challa, P R Hof and G W Van Hoesen: Multivariate analysis of laminar patterns of neurodegeneration in posterior cingulate cortex in Alzheimer's disease. Exp Neurol 153(1), 8-22 (1998)
66. S Maeda, N Sahara, Y Saito, M Murayama, Y Yoshiike, H Kim, T Miyasaka, S Murayama, A Ikai and A Takashima: Granular tau oligomers as intermediates of tau filaments. Biochemistry 46(12), 3856-61 (2007)
67. S Maeda, N Sahara, Y Saito, S Murayama, A Ikai and A Takashima: Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res 54(3), 197-201 (2006)
68. M Yamazaki, M Hasegawa, O Mori, S Murayama, K Tsuchiya, K Ikeda, K M. Chen, Y Katayama and K Oyanagi: Tau-positive fine granules in the cerebral white matter: a novel finding among the tauopathies exclusive to parkinsonism- dementia complex of Guam. J Neuropathol Exp Neurol 64(10), 839-46 (2005)
69. C A Lasagna-Reeves, D L Castillo-Carranza, U Sengupta, J Sarmiento, J Troncoso, G R Jackson and R Kayed: Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J (2012)
70. K R Patterson, C Remmers, Y Fu, S Brooker, N M Kanaan, L Vana, S Ward, J F Reyes, K Philibert, M J Glucksman and L I Binder: Characterization of prefibrillar tau oligomers in vitro and in Alzheimers disease. J Biol Chem (2011)
71. F Clavaguera, T Bolmont, R A Crowther, D Abramowski, S Frank, A Probst, G Fraser, A K Stalder, M Beibel, M Staufenbiel, M Jucker, M Goedert and M Tolnay: Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11(7), 909-13 (2009)
72. B Frost and M I Diamond: Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci, 11(3), 155-9 (2010)
73. P Brundin, R Melki and R Kopito: Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11(4), 301-7 (2010)
74. R C Pearson, M M Esiri, R W Hiorns, G K Wilcock and T P Powell: Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci U S A 82(13), 4531-4 (1985)
75. A Delacourte, N Sergeant, A Wattez, C A Maurage, F Lebert, F Pasquier and J P David: Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp Gerontol 37(10-11), 1291-6 (2002)
76. G Lace, G M Savva, G Forster, R de Silva, C Brayne, F E Matthews, J J Barclay, L Dakin, P G Ince and S B Wharton: Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study. Brain 132(Pt 5), 1324-34 (2009)
77. J P Brion, G Tremp and J N Octave: Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. Am J Pathol 154(1), 255-70 (1999)
78. T Ishihara, M Hong, B Zhang, Y Nakagawa, M K Lee, J Q Trojanowski and V M Lee: Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24(3), 751-62 (1999)
79. A Probst, J Gotz, K H Wiederhold, M Tolnay, C Mistl, A L Jaton, M Hong, T Ishihara, V M Lee, J Q Trojanowski, R Jakes, R A Crowther, M G Spillantini, K Burki and M Goedert: Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol 99(5), 469-81 (2000)
80. K Spittaels, C Van den Haute, J Van Dorpe, K Bruynseels, K Vandezande, I Laenen, H Geerts, M Mercken, R Sciot, A Van Lommel, R Loos and F Van Leuven: Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 155(6), 2153-65 (1999)
81. J Gotz, A Probst, M G Spillantini, T Schafer, R Jakes, K Burki and M Goedert: Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 14(7), 1304-13 (1995)
82. H Rosenmann, N Grigoriadis, H Eldar-Levy, A Avital, L Rozenstein, O Touloumi, L Behar, T Ben-Hur, Y Avraham, E Berry, M Segal, I Ginzburg and O Abramsky: A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp Neurol 212(1), 71-84 (2008)
83. K Schindowski, A Bretteville, K Leroy, S Begard, J P Brion, M Hamdane and L Buee: Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169(2), 599-616 (2006)
84. D Terwel, R Lasrado, J Snauwaert, E Vandeweert, C Van Haesendonck, P Borghgraef and F Van Leuven: Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem 280(5), 3963-73 (2005)
85. B Zhang, M Higuchi, Y Yoshiyama, T Ishihara, M S Forman, D Martinez, S Joyce, J Q Trojanowski and V M Lee: Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy. J Neurosci 24(19), 4657-67 (2004)
86. K Tanemura, M Murayama, T Akagi, T Hashikawa, T Tominaga, M Ichikawa, H Yamaguchi and A Takashima: Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J Neurosci 22(1), 133-41 (2002)
87. Y Tatebayashi, T Miyasaka, D H Chui, T Akagi, K Mishima, K Iwasaki, M Fujiwara, K Tanemura, M Murayama, K Ishiguro, E Planel, S Sato, T Hashikawa and A Takashima: Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc Natl Acad Sci U S A 99(21), 13896-901 (2002)
88. F Lim, F Hernandez, J J Lucas, P Gomez-Ramos, M A Moran and J Avila: FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol Cell Neurosci 18(6), 702-14 (2001)
89. J Lewis, E McGowan, J Rockwood, H Melrose, P Nacharaju, M Van Slegtenhorst, K Gwinn-Hardy, M Paul Murphy, M Baker, X Yu, K Duff, J Hardy, A Corral, W L Lin, S H Yen, D W Dickson, P Davies and M Hutton: Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25(4), 402-5 (2000)
90. J Gotz, F Chen, R Barmettler and R M Nitsch: Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276(1), 529-34 (2001)
91. T L Spires, J D Orne, K SantaCruz, R Pitstick, G A Carlson, K H Ashe and B T Hyman: Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 168(5), 1598-607 (2006)
92. C Andorfer, C M Acker, Y Kress, P R Hof, K Duff and P Davies: Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25(22), 5446-54 (2005)
93. C Andorfer, Y Kress, M Espinoza, R de Silva, K L Tucker, Y A Barde, K Duff and P Davies: Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86(3), 582-90 (2003)
94. M Polydoro, C M. Acker, K Duff, P E Castillo and P Davies: Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci 29(34), 10741-9 (2009)
95. S Le Corre, H W Klafki, N Plesnila, G Hubinger, A Obermeier, H Sahagun, B Monse, P Seneci, J Lewis, J Eriksen, C Zehr, M Yue, E McGowan, D W Dickson, M Hutton and H M Roder: An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A 103(25), 9673-8 (2006)
96. Y Yoshiyama, M Higuchi, B Zhang, S M. Huang, N Iwata, T C Saido, J Maeda, T Suhara, J Q Trojanowski and V M Lee: Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53(3), 337-51 (2007)
97. J Xu, S Sato, S Okuyama, R J Swan, M T Jacobsen, E Strunk and T Ikezu: Tau-Tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP-17 tau-mutant mice. FASEB J (2010)
98. E D Roberson and L Mucke: 100 years and counting: prospects for defeating Alzheimer's disease. Science 314(5800), 781-4 (2006)
99. R S Shah, H G Lee, Z Xiongwei, G Perry, M A Smith and R J Castellani: Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother 62(4), 199-207 (2008)
100. C I Stains, K Mondal and I Ghosh: Molecules that target beta-Amyloid. ChemMedChem 2(12), 1674-92 (2007)
101. D W Klaver, M C Wilce, H Cui, A C Hung, R Gasperini, L Foa and D H. Small: Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions. Biol Chem 391(8), 849-59 (2010)
102. T Kovacs: Therapy of Alzheimer disease. Neuropsychopharmacol Hung 11(1), 27-33 (2009)
103. M S Wolfe: Inhibition and modulation of gammasecretase for Alzheimer's disease. Neurotherapeutics 5(3), 391-8 (2008)
104. D Morgan: Immunotherapy for Alzheimer's disease. J Intern Med 269(1), 54-63 (2011)
105. D Schenk: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3(10), 824-8 (2002)
106. C Holmes, D Boche, D Wilkinson, G Yadegarfar, V Hopkins, A Bayer, R W Jones, R Bullock, S Love, J W Neal, E Zotova and J A Nicoll: Long-Term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 372(9634), 216-23 (2008)
107. D Boche, E Zotova, R O Weller, S. Love, J W Neal, R M Pickering, D Wilkinson, C Holmes and J A Nicoll: Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 131(Pt 12), 3299-310 (2008)
108. H Rosenmann, N Grigoriadis, D Karussis, M Boimel, O Touloumi, H Ovadia and O Abramsky: Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 63(10), 1459-67 (2006)
109. A A Asuni, A Boutajangout, D Quartermain and E M Sigurdsson: Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27(34), 9115-29 (2007)
110. M Boimel, N Grigoriadis, A Lourbopoulos, E Haber, O Abramsky and H Rosenmann: Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224(2), 472-85 (2010)
111. K Duff, C Eckman, C Zehr, X Yu, C M. Prada, J Perez-Tur, M Hutton, L Buee, Y Harigaya, D Yager, D Morgan, M N Gordon, L Holcomb, L Refolo, B Zenk, J Hardy and S Younkin: Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383(6602), 710-3 (1996)
112. A Boutajangout, D Quartermain and E M Sigurdsson: Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30(49): 16559-66. (2010)
113. A Boutajangout, J Ingadottir, P Davies and E M Sigurdsson: Passive immunization targeting pathological phospho-Tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118(4), 658-67. (2011)
114. J C Augustinack, A Schneider, E M Mandelkow and B T Hyman: Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103(1), 26-35 (2002)
115. X Chai, S Wu, T K Murray, R Kinley , C V Cella, H Sims, N Buckner, J Hanmer, P Davies, M J O'Neill, M Hutton and M Citron: Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem (2011)
116. D L Castillo-Carranza, C A Lasagna-Reeves, M J Guerrero-Munoz, D M Estes, A Barrett, K Dineley, G R Jackson and R Kayed: Modulation of tau oligomers by passive vaccination. Soc Neurosci Abstr 347.11 (2010)
117. B J Balin, R D Broadwell, M Salcman and M el-Kalliny: Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 251(2), 260-80 (1986)
118. R D Broadwell and M V Sofroniew: Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system. Exp Neurol 120(2), 245-63 (1993)
119. B V Zlokovic, D S Skundric, M B Segal, M N Lipovac, J B Mackic and H Davson: A saturable mechanism for transport of immunoglobulin G across the blood-brain barrier of the guinea pig. Exp Neurol 107(3), 263-70 (1990)
120. N Kobayashi, Y Suzuki, T Tsuge, K Okumura, C Ra and Y Tomino: FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Am J Physiol Renal Physiol 282(2), F358-65 (2002)
121. E M Sigurdsson: Immunotherapy for conformational diseases. Curr Pharm Des 12(20), 2569-85 (2006)
122. E M Sigurdsson: Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 15(2), 157-68 (2008)
123. C Hesse, L Rosengren, N Andreasen, P Davidsson, H Vanderstichele, E Vanmechelen and K Blennow: Transient increase in total tau but not phospho-Tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297(3), 187-90 (2001)
124. W Kim, S Lee, C Jung, A Ahmed, G Lee and G F Hall: Interneuronal transfer of human tau between Lamprey central neurons in situ. J Alzheimers Dis 19(2): 647-64. (2010)
125. K Yamada, J R Cirrito, F R Stewart, H Jiang, M B Finn, B B Holmes, L I Binder, E M Mandelkow, M I Diamond, V M Lee and D M Holtzman: In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 31(37), 13110-7 (2011)
126. B Frost, J Ollesch, H Wille and M I Diamond: Conformational diversity of wild-Type Tau fibrils specified by templated conformation change. J Biol Chem 284(6), 3546-51 (2009)
127. P K Krishnamurthy, Y Deng and E M Sigurdsson: Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model. Front Psychiatry 2, 59 (2011)
128. R B DeMattos, K R Bales, D J Cummins, J C Dodart, S M Paul and D M Holtzman: Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98(15), 8850-5 (2001)
129. D Morgan: The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS Neurol Disord Drug Targets 8(1), 7-15 (2009)